Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non-Hodgkin's lymphoma and multiple myeloma patients. T...

詳細記述

保存先:
書誌詳細
出版年:Pharmacol Res Perspect
主要な著者: Ackler, Scott, Oleksijew, Anatol, Chen, Jun, Chyla, Brenda J, Clarin, Jerry, Foster, Kelly, McGonigal, Thomas, Mishra, Sasmita, Schlessinger, Sally, Smith, Morey L, Tahir, Stephen K, Leverson, Joel D, Souers, Andrew J, Boghaert, Erwin R, Hickson, Jonathan
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Ltd 2015
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618648/
https://ncbi.nlm.nih.gov/pubmed/26516589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.178
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料